Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fentanyl
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aveva Launches Generic Fentanyl TDS, Third Complex Transdermal Drug in 15 Months
Details : Fentanyl TDS, a prescriptional 3-day transdermal patch is launched for managing moderate to severe chronic pain which is generic equivalent to Duragesic.
Product Name : Duragesic-Generic
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 17, 2025
Lead Product(s) : Fentanyl
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
